Documents

Strong H1 growth driven by Rare Disease and U.S. performance, with guidance reaffirmed.

Rare disease drove robust Q1 growth, with ISTURISA and Enjaymo outperforming expectations.

Rare disease growth and new indications drive robust outlook, with 2025 targets on track.

Strong 2025 growth driven by rare disease, robust margins, and strategic partnerships.

Rare disease growth accelerates, Isturisa guidance raised, and 2026 set as a key investment year.

Isturisa’s peak sales estimate doubled to €1.2B+ as rare disease and U.S. growth accelerate.

Double-digit revenue and EBITDA growth, with rare diseases nearing 40% of total revenue.

Q1 revenue up 11.9% to €680M, EBITDA margin 39.7%, 2025 and 2027 growth targets confirmed.

Double-digit growth and margin expansion targeted through 2027, with revenue set to double by 2030.

Recordati posts robust 2024 growth, lifts rare disease sales targets for 2025.